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ABSTRACT 
Concise total syntheses of linear thiazole-containing peptides virenamides A (1) and D (4), isolated from Australian 
ascidian Diplosoma virens have been accomplished from Boc-L-valine (6) in 7 steps. A cyclization between thioamide and 
bromoacetaldehyde was applied to form thiazole ring as a key step. 
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INTRODUCTION  
Marine natural products are a rich source of novel peptides, many of which show high levels of biological activity [1-3]. 
For example, the thiazole-containing cyclic peptide largazole exhibits extremely potent antiproliferative activity against a 
number of cancer cell-lines including MDA-MB-231 mammary cells (GI50 7.7 nM), U2OS fibroblastic osteosarcoma cells 
(GI50 55 nM), HT29 colon cells (GI50 12 nM), and IMR-32 neuroblastoma cells (GI50 16 nM) and linear thiazole-containing 
peptide dolastatin 10 is one of the most potent antineoplastic agents [4-5]. Over a decade ago, Bowden et. al isolated five 
cytotoxic linear peptides virenamides A-E (1-5) from Australian ascidian Diplosoma virens and assigned their structures by 
extensive NMR experiments [6-7]. In 1999, Moody et. al had reported a stereoselective synthesis of virenamide B (2) in 
which an elegant diastereoselective addition of 2-lithiothiazole to oxime ether was applied to construct the thiazole ring in 
excellent yield and diastereomeric excess [8]. For a long term concern, we initiated the total synthesis of virenamides in 
order to investigate the potential bioactivity of the derivatives. Herein, we report the concise efficient total syntheses of 
virenamides A (1) and D (4) from accessible  starting material Boc-L-valine (6), which would provide enough product for 
further biological studies. 
 
Fig. 1 Chemical structures of virenamides A-E (1-5) 
Our initial retrosynthetic analysis of 1 and 4 is outlined in Scheme 1. We envisaged that the thiazole ring of 1 and 4 
could be constructed through a cyclization between thioamide 9 and bromoacetaldehyde 10. Thioamide 9 in turn could be 
obtained from a cheap starting material Boc-L-valine (6). 
 
Scheme 1. Retrosynthetic analysis of virenamide A (1) and D (4) 
EXPERIMENTAL PROCEDURE 
Melting points (mp) are uncorrected and were measured on a microscopic melting point apparatus. The IR spectra 
were recorded on a Bruker Tensor 27 FT-IR spectrometer with a KBr disk. The 
1
H NMR and 
13
C NMR spectra were taken 
on a Bruker AV 300 or AV 500 MHz and 75 or 125 MHz spectrometer in CDCl3, chemical shift are given in part per million 
(ppm) relative to TMS as an internal standard. Mass spectra and High Resolution Mass spectra were performed on Agilent 
Q TOF 6520 mass spectrometer with electron spray ionization (ESI) as the ion source. Optical rotations were recorded 
using a sodium lamp with a Rudolph Autopol I Automatic Polarimeter with 1 dm tube. (S)-tert-butyl 1-amino-3-methyl-1-
oxobutan-2-ylcarbamate (7) [9], (S)-tert-butyl 1-amino-3-methyl-1-thioxobutan-2-ylcarbamate (9) [10-12], (S)-2-methyl-1-
(thiazol-2-yl)propan-1-amine hydrochloride (12) [8], and (S)-2-((S)-2-(tert-butoxycarbonylamino)-3-phenylpropanamido)-3-
methylbutanoic acid (13) [15], were prepared following the literature procedures. 
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(S)-(-)-N-(tert-butoxycarbonyl)-1-(2-thiazolyl)-2-methylpropylamine (11) 
DIPEA (2.09 g, 16 mmol) was added to a solution of compoumd 9 (0.928g, 4 mmol) in anhydrous DME (16 mL). 
Bromoacetaldehyde 10 (1.48g, 12 mmol)
 
 was added and the solution was stirred at rt for 14 h. The mixture was 
evaporated in vacuo and the residue was partitioned between H2O (96 mL) and Et2O (48 mL). The aqueous layer was 
further extracted with Et2O (48 mL) and the combined organic extracts were washed with brine (24 mL), dried (Na2SO4) 
and evaporated in vacuo. The residue was re-dissolved in anhydrous DME (15 mL) and cooled to 0 °C. A solution of 
TFAA (1.34 g, 5.6 mmol) and dry Pyridine (1.02 g, 12.8 mmol) in anhydrous DME (4.5 mL) was added and the solution 
was stirred at 0 °C for 0.5 h. The reaction mixture was evaporated in vacuo. The residue was dissolved in CHCl3 (75 mL), 
washed with H2O (40 mL) and brine (40 mL). Evaporation of the solvent followed by purification on silica gel afforded 
colorless oil 11 (0.839 g, 82%, ee 94.5%). [α]D
20
 -32.9
o
 (c 1.10, CHCl3); IR spectrum (CHCl3) νmax/cm
-1
: 3298 (NH), 1703 
(C=O), 
1
H NMR spectrum (300 MHz, CDCl3) δ 7.67 (d, 1H, J 3.3 Hz, thiazole H-1), 7.17 (d, 1H, J 3.3 Hz, thiazole H-2), 
5.21 (br d, 1H, J  8.9 Hz, NH), 4.84 (dd, 1H, J  5.5, 8.9 Hz, CHNH), 2.30-2.23 (m, 1H, CHMe2), 1.38 (br s, 9H, 3CH3), 0.90 
(d, 3H, J 6.8 Hz, CH3), 0.85 (d, 3H, J 6.8 Hz, CH3). Spectral data of 11 were identical to those described in reference [8]. 
N-(tert-butoxycarbonyl)-L-phenylalanyl-N-[(S)-(-)-1-(thiazole-2-yl)-2-methyl-propyl]-L-valinamide (14) 
Compound 13 (0.262 g, 0.72 mmol) was dissolved in dry THF (8 mL) under nitrogen and cooled to 0 °C. N-
Methylmorpholine (0.219 g, 2.16 mmol) and iso-butyl chloroformate (0.099 g, 0.72 mmol) were added sequentially to the 
solution and stirred for 50 min. Compound 12 (0.115 g, 0.60 mmol) in dry DMF (2 mL) was added in one portion, and the 
mixture was stirred for 1 h. Water, brine, and EtOAc were added, and the layers were separated. The aqueous phase was 
further extracted with EtOAc. The combined EtOAc extracts were washed with water, dried (Na2SO4), filtered, and 
evaporated. The residue was purified by column chromatography on silica gel to give colorless syrup 14 (0.163 g, 54% 
yield). [α]D
25 
-50.1 (c 0.90, CHCl3); IR spectrum (CHCl3) νmax/cm
-1
: 3342 (NH), 3275 (NH), 3030(CHarom.), 2962 (CHaliph.), 
1690 (C=O), 1675 (C=O),1643 (C=O); 
1
H NMR spectrum (300 MHz, CDCl3) δ 7.85 (1H, d, J 8.4 Hz, NH), 7.78 (1H, d, J 
3.3 Hz, thiazole H-4), 7.16-7.27 (5H, m, Ar-H), 7.23 (1H, d, J 3.3 Hz, thiazole H-5), 7.08 (1H, br d, J 8.4 Hz, NH), 5.82 (1H, 
br d, J 7.2 Hz, NHBoc), 5.24 (1H, dd, J 6.9, 9.0 Hz, CH), 4.52 (2H, br t, J 8.1 Hz, 2CH), 2.96-3.11 (2H, m, CH2Ph), 2.36-
2.46 (1H, m, CHMe2), 2.04-2.11 (1H, m, CHMe2), 1.36 (9H, s, 3CH3), 0.91-0.96 (6H, m, 2CH3), 0.84-0.87 (6H, m, 2CH3);
 
13
C NMR spectrum (75 MHz, CDCl3) δ 171.9, 170.9 (C=O), 170.6 (thiazole C-3), 155.5 (C=O), 142.7 (thiazole C-1), 136.7, 
129.2, 128.4, 126.7 (aromatic), 118.1 (thiazole C-2), 79.7, 58.8, 56.0, 55.7, 37.8, 33.3, 30.8, 28.2, 19.3, 19.1, 18.3, 18.0 
(aliphatic); HRMS (ESI) calcd. for C26H38N4O4S [M+H]: 503.2687; found 503.2692.  
(S)-2-((S)-2-(bis(3-methylbut-2-enyl)amino)-3-phenylpropanamido)-3-methyl-N-((S)-2-methyl-1-(thiazol-2-yl)propyl) 
butanamide (virenamide A, 1) 
To a solution of compound 15 (47 mg, 0.106 mmol) in 2.7 mL dry DMF, TBAI (8 mg, 0.0212 mmol), prenyl bromide 
(66 mg, 0.424 mmol) and NaHCO3 (54 mg, 0.636 mmol) were added sequentially at rt and the mixture was stirred at 70 
o
C 
for 2 h. The solution was cooled to rt. Water (5 mL), brine (5 mL), and EtOAc (10 mL) were added, and the EtOAc extracts 
were separated. The aqueous phase was further extracted with EtOAc (10 mL). The combined EtOAc extracts was 
washed with brine (4 mL), dried (Na2SO4), filtered, and evaporated. The residue was purified by column chromatography 
on silica gel to give virenamide A 1 (52 mg, 91% yield). [α]D
21
 -35.5 (c 0.16, CHCl3). (lit. 
6
 [α]D -34.1 (c 0.14, CHCl3); IR 
(CHCl3) νmax/cm
-1
: 3405 (NH), 3318 (NH), 3026 (CHarom.), 2964 (CHaliph.), 2928 (CHaliph.), 1647 (C=O); 
1
H NMR spectrum 
(300 MHz, CDCl3) δ 7.82 (d, 1H, J 8.8 Hz, NH), 7.68 (d, 1H, J 3.3 Hz, thiazole H-1), 7.16-7.25 (m, 5H, Ar-H), 7.21 (d, 1H, J 
3.3 Hz, thiazole H-2), 6.82 (d, 1H, J 8.8 Hz, NH), 5.19 (dd, 1H, J 5.4, 8.8 Hz, CH-4), 5.13 (t, 2H, J 6.7 Hz, =CH-21), 4.21 
(dd, 1H, J 6.7, 8.8 Hz, CH-9), 3.75 (dd, 1H, J 6.3, 6.5 Hz, CH-14), 3.31 (dd, 1H, J 6.6, 14.2 Hz, CH-15), 3.08 (d, 4H, J 6.6 
Hz, 2CH2-20), 2.88 (dd, 1H, J 6.0, 14.1 Hz, CH-15), 2.33 (dqq, 1H, J 5.7, 6.2, 6.3 Hz, CHMe2-5), 2.27 (dqq, 1H, J 6.8, 6.8, 
6.8 Hz, CHMe2-10), 1.69 (s, 6H, 2CH3-24), 1.55 (s, 6H, 2CH3-23), 0.95 (d, 3H, J 6.7 Hz, CH3-12), 0.94 (d, 3H, J 6.8 Hz, 
CH3-11), 0.86 (d, 3H, J 6.3 Hz, CH3-7), 0.84 (d, 3H, J 6.2 Hz, CH3-6). 
13
C NMR spectrum (125 MHz, CDCl3) δ 174.2, 170.9 
(C=O), 170.6 (thiazole C-3), 142.5 (thiazole C-1), 140.9 (aromatic), 135.5 (C-22), 129.2, 128.3, 125.8 (aromatic), 122.0 (C-
21), 118.3 (thiazole C-2), 64.8, 58.7, 56.1, 48.2, 33.3, 31.0, 29.7, 25.8, 19.5, 19.1, 18.1, 17.9, 17.3 (aliphatic); MS m/z (%): 
539 (100), 471 (50), 431 (45); HRMS (ESI) calcd. for C31H46N4O2S [M+H]: 539.3414; found 539.3409. 
(S)-3-methyl-N-((S)-2-methyl-1-(thiazol-2-yl)propyl)-2-((S)-2-(3-methylbut-2-enylamino)-3-phenylpropanamido) 
butanamide (virenamide D, 4) 
To a solution of compound 15 (47 mg, 0.106 mmol) in 2.7 mL dry DMF, TBAI (4 mg, 0.0106 mmol), prenyl bromide 
(33 mg, 0.212 mmol) and NaHCO3 (36 mg, 0.424 mmol) were added sequentially at rt and the mixture was stirred at 70 
o
C 
for 2 h. The solution was cooled to rt. Water (5 mL), brine (5 mL), and EtOAc (10 mL) were added, and the EtOAc extracts 
were separated. The aqueous phase was further extracted with EtOAc (10 mL). The combined EtOAc extracts were 
washed with brine (4 mL), dried (Na2SO4), filtered, and evaporated. The residue was purified by column chromatography 
on silica gel to give virenamide D 4 (39 mg, 79% yield). [α]D
21
 -65.6 (c 0.25, CHCl3) (lit. 
7
 [α]D -65 (c 0.07, CHCl3); IR 
(CHCl3) νmax/cm
-1
: 3409 (NH), 3310 (NH), 3019 (CHarom.), 2963 (CHaliph.), 2929 (CHaliph.), 1644 (C=O); 
1
H NMR spectrum 
(300 MHz, CDCl3) δ 7.96 (d, 1H, J 9.1 Hz, NH), 7.72 (d, 1H, J 3.3 Hz, thiazole H-1), 7.20-7.34 (m, 5H, Ar-H), 7.22 (d, 1H, J 
3.3 Hz, thiazole H-2), 7.09 (d, 1H, J 8.8 Hz, NH), 5.24 (dd, 1H, J 5.7, 8.9 Hz, CH-4), 4.98 (br t, 1H, J 7.6 Hz, =CH-21), 4.28 
(dd, 1H, J 7.3, 9.0 Hz, CH-9), 3.37 (dd, 1H, J 3.9, 9.7 Hz, CH-14), 3.25 (dd, 1H, J 13.8, 3.9 Hz, CH-15), 3.10 (br dd, 1H, J 
13.3, 7.6 Hz, CH-20), 2.98 (br dd, 1H, J 13.3, 7.6 Hz, CH-20), 2.69 (dd, 1H, J 13.8, 9.7 Hz, CH-15), 2.37(dqq, 1H, J 5.5, 
6.8, 6.8 Hz, CHMe2-5), 2.22 (dqq, 1H, J 7.7, 6.6, 6.6 Hz, CHMe2-10), 1.63 (s, 3H, CH3-24), 1.46 (s, 3H, CH3-23), 1.40 (br, 
1H, NH), 0.94 (d, 3H, J 6.7 Hz, CH3-7), 0.92 (d, 3H, J 6.7 Hz, CH3-6), 0.92 (d, 3H, J 6.7 Hz, CH3-11), 0.89 (d, 3H, J 6.7 Hz, 
CH3-12). 
13
C NMR spectrum (75 MHz, CDCl3) δ 174.3, 170.9 (C=O), 170.6 (thiazole C-3), 142.6 (thiazole C-1), 137.4 
(aromatic), 135.5 (C-22), 129.1, 128.7, 126.9 (aromatic), 121.8 (C-21), 118.3 (thiazole C-2), 63.1, 58.6, 56.1, 46.0, 39.3, 
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33.4, 30.1, 25.6, 19.5, 19.2, 18.1, 17.6, 17.6 (aliphatic); MS m/z (%): 471 (100), 427 (45), 413 (40); HRMS (ESI) calcd. for 
C26H38N4O2S [M+H]: m/z 471.2788; found 471.2784. 
Scheme 2. The synthesis of Virenamides A (1) and D (4). Reagents and conditions: (a) ClCOOEt, TEA, dry THF, 0 
o
C, 
1h; 25% NH4OH, r.t., 1h, 94%; (b) Lawesson’s reagent 8, dry CH2Cl2, reflux, 16h, 79%; (c) (i) BrCH2CHO, DIPEA, dry 
DME, r.t., 14h; (ii) TFAA, dry pyridine, dry DME, 0 
o
C, 0.5h, 82% in two steps; (d) Acetyl chloride, dry MeOH, r.t., 4h, 
quantitative; (e) ClCOOBu-i, NMM, dry THF, 0 
o
C, 1h, r.t., 1h, 54%; (f) Acetyl chloride, dry MeOH, r.t., 4h, quantitative; (g) 
Prenyl bromide, DIPEA, TBAI, dry DMF, 70 
o
C, 2h, 91%; (h) Prenyl bromide, NaHCO3, TBAI, dry DMF, r.t., 5h, 79%. 
RESULTS AND DISCUSSION 
In the present work we report the first total synthesis of virenamides A and D based on N-(tert-butoxycarbonyl)-L-
phenylalanyl-N-[(S)-(-)-1-(thiazole-2-yl)-2-methyl-propyl]-L-valinamide (14), which was prepared from (S)-(-)-N-(tert-
butoxycarbonyl)-1-(2-thiazolyl)-2-methylpropylamine (11) [13], as key intermediate. As illustrated in Scheme 1, the 
cyclization of thiamide 9 [9-12] with bromoacetaldehyde 10 to form thiazole is the key step for synthesis of Virenamides A 
and D and is crucial as it is prone to epimerization at the α-stereogenic center. We optimized the reaction conditions for 
this conversion. As can be seen from Table 1, when bromoacetaldehyde 10 effected the reaction (Entries 1, 2, no base), 
the deprotection of Boc group of 11 was observed because of the acidic condition where the simultaneous release of HBr 
during the cyclization. Thus, we treated the cyclization reaction mixture with Boc2O/TEA to get 11 in moderate yield, but 
HBr in the reaction mixture resulted in almost entirely racemization of the product [13]. Based on what the literature 
described [13], we tried several inorganic bases and organic bases to form thiazoline intermediate, which was used for 
next step without purification. Dehydration of thiazoline intermediate afforded 11 in different yields and ee values. Although 
inorganic base could give high yield in general (Entries 4, 5), it was found that organic base yield much better ee value 
(Entries 7-9). DIPEA was proved to be the best acid trapper, which gave a yield of 82% with 94.5% ee (Entry 7) according 
to chiral-HPLC analysis [14].  
Having synthesized the key intermediate 11, the next step was to prepare intermediate 14. We should prepare 
dipeptide 13 firstly, which was through a two-step sequence. Boc-(L)-Phenylalanine was reacted with L-valine methyl ester 
to give dipeptide ester in 95% yield, which was saponificated with 1M NaOH/THF to give dipeptide 13 [15] in 94% yield.
 
Then the synthesis of 14 was achieved in two steps including removal of Boc group from 11 to provide amine 
hydrochloride 12 [8], Coupling of 12 with dipeptide 13 with ClCOOBu-i/NMM to give tripeptide 14 in 54% yield  [16]. 
Likewise, removal of Boc group from 14 with AcCl in MeOH smoothly provided amine hydrochloride 15 in almost 
quantitative yield, which was used for next step without further purification.  
Finally, double alkylation of amine 15 with 4 equiv prenyl bromide in DMF at 70 ºC for 2 h afforded virenamide A (1) in 
91% yield as a colorless oil ([α]D
25
 -35.5, c 0.16 in CHCl3),  while mono-alkylation of 15 with 2 equiv prenyl bromide in DMF 
at room temperature for 5 h smoothly furnished virenamide D (4) in 79% yield as a colorless oil ([α]D
21
 -65.6, c 0.25 in 
CHCl3). 
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The structures of compound 1 and 4 were determined from spectroscopic as well as optical rotation analytical data, 
which were consistent with those described for the ntatural products [6-7]. The 
1
H NMR spectrum of compound 1 revealed 
a double signal at δ 3.08 ppm (J 6.6 Hz) due to =CH protons, a triple signal at δ 5.13 ppm (J 6.7 Hz) due to CH2 protons, 
two single signals at δ 1.55 and δ 1.69 due to C22. The high resolution mass spectrum of compound 1 showed [M+H]
+
 at 
539.3409 which is coincident with calculated [M+H]
+ 
(539.3414) as the molecular formula C31H46N4O2S. While, the 
1
H 
NMR spectrum of compound 4 showed a dd signal at δ 3.10 and 2.98 ppm (J 13.3, 7.6 Hz) due to =CH molecular formula , 
a broad triple signal at δ 4.98 ppm (J 7.6 Hz) due to CH2 protons, two single signals at δ 1.46 and δ 1.63 due to C22. The 
high resolution mass spectrum of compound 4 showed [M+H]
+
 at 471.2784 which is coincident with calculated [M+H]
+ 
(471.2788) as the molecular formula C26H38N4O2S. Analytical  data  for  new  compound  and copies  of 
1
H  NMR  and 
13
C  
NMR  spectra  can  be  found  in  supporting information. 
Table 1. Optimization of reaction conditions
a
 
Step 1 Step 2 
Entry 
Mol. ratio 
(9:10:Base) 
Solvent T Base T Reagents 
Yield 
(%)
c
 
ee 
(%)
b
 
1 1:1.1 Dioxane r.t.  r.t. (Boc)2O (1 eq), TEA (1.1 eq) 68 8 
2 1:1.1 DME r.t.  r.t. (Boc)2O (1 eq), TEA (1.1 eq) 67 6.5 
3 1:3:4 DME r.t. KHCO3 0 
o
C TFAA (1.4 eq), Pyr (3.2 eq) 76 66 
4 1:3:4 DME 0 
o
C KHCO3 0 
o
C TFAA (1.4 eq), Pyr (3.2 eq) 80
d
 61 
5 1:3:4 DME r.t. NaHCO3 0 
o
C TFAA (1.8 eq), Pyr (4.1 eq) 82 70 
6 1:3:3 DME r.t. K2CO3 0 
o
C TFAA (1.4 eq), Pyr (3.2 eq) 69 86 
7 1:3:4 DME r.t. DIPEA 0 
o
C TFAA (1.4 eq), Pyr (3.2 eq) 82 94.5 
8 1:3:4 DME r.t. TEA 0 
o
C TFAA (1.4 eq), Pyr (3.2 eq) 59 93 
9 1:7:8 DME r.t. NMM 0 
o
C TFAA (1.1 eq), Pyr (2.6 eq) 62
e
 76 
a
 Reactions were performed on a 0.5 mmol scale. 
b 
The ee values were calculated according to reference 8 (entries 3-6, 8, 9) or determined by chiral-HPLC (entries 2, 7). 
c
 Isolated yields after flash column chromatography. 
d
 The starting material was completely consumed after 36 h. 
e
 The starting material was not completely consumed after 36 h. 
CONCLUSIONS 
In summary, we have developed a very concise route for the first total syntheses of virenamide A and D starting from Boc-
L-valine in 7-steps (overall yields: 26% for virenamide A; 22% for virenamide D). Syntheses of these natural products and 
their derivatives in large scale could be realized by this route, which facilitates further biological experiments. Studies 
towards the structure modifications of these natural products for further pharmacological investigation are ongoing.  
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